Nucleic Acid, Nucleoside, or Nucleotide – Page 7

FDA Places Clinical Hold on Atara Biotherapeutics’ EBVALLO and ATA3219 Due to Manufacturing Compliance Issues

8 months ago talkbio0Tagged allogeneic T-cell therapies, Atara Biotherapeutics, Biomechanical compliance, Ebvallo, Epstein-Barr virus, GMP, Guanosine Monophosphate, Lupus Erythematosus, Systemic, Manufacturing, Post-transplant lymphoproliferative disorder, Study on Hold, United States Food and Drug Administration

Atara Biotherapeutics, FDA clinical hold, EBVALLO, ATA3219, allogeneic T-cell therapies, manufacturing compliance issues, GMP compliance, Epstein-Barr virus, post-transplant lymphoproliferative disease, non-Hodgkin’s lymphoma, systemic lupus erythematosus.

Sanofi Assures No Supply Disruptions Following FDA Warning Letter for US Manufacturing Site

8 months ago talkbio0Tagged Cautionary Warning, Cyclic GMP, deviations, interruptions, Letter [Publication Type], manufacturing site, sanofi, U.S., United States Food and Drug Administration

Sanofi, FDA warning letter, US manufacturing site, supply interruptions, CGMP deviations

Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna

8 months ago talkbio0Tagged Chien, deal, Etherna, Kenneth, Moderna, mRNA therapies, RNA

Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

8 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines

8 months ago talkbio0Tagged cardiometabolic disease, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, epigenetic modification, Gene Modification

Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

8 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine

FDA Approves Ionis’s TRYNGOLZA for Familial Chylomicronemia Syndrome, a Rare Metabolic Disorder

9 months ago talkbio0Tagged Approved, Familial chylomicronemia syndrome, Metabolic Diseases, Olezarsen, TRYNGOLZA, United States Food and Drug Administration

FDA approval, Ionis Pharmaceuticals, TRYNGOLZA, olezarsen, familial chylomicronemia syndrome (FCS), rare metabolic disorder

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

9 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology